Zoccali C - Search Results

1

The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.

Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C. Yilmaz MI, et al. Among authors: zoccali c. Am J Kidney Dis. 2006 Jan;47(1):42-50. doi: 10.1053/j.ajkd.2005.09.029. Am J Kidney Dis. 2006. PMID: 16377384

2

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.

Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R; CREED Investigators. Zoccali C, et al. Kidney Int. 2002 Jul;62(1):339-45. doi: 10.1046/j.1523-1755.2002.00437.x. Kidney Int. 2002. PMID: 12081596 Free article.

3

Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.

Zoccali C. Zoccali C. Blood Purif. 2002;20(5):469-72. doi: 10.1159/000063550. Blood Purif. 2002. PMID: 12207095

4

Low parathyroid hormone and pentosidine in hemodialysis patients.

Panuccio V, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Asahi K, Miyata T, Zoccali C. Panuccio V, et al. Among authors: zoccali c. Am J Kidney Dis. 2002 Oct;40(4):810-5. doi: 10.1053/ajkd.2002.35693. Am J Kidney Dis. 2002. PMID: 12324917

5

Achievement of target blood pressure levels in chronic kidney disease: a salty question?

De Nicola L, Minutolo R, Bellizzi V, Zoccali C, Cianciaruso B, Andreucci VE, Fuiano G, Conte G; investigators of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group. De Nicola L, et al. Among authors: zoccali c. Am J Kidney Dis. 2004 May;43(5):782-95. doi: 10.1053/j.ajkd.2004.01.009. Am J Kidney Dis. 2004. PMID: 15112168 Review.

6

Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.

Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Mallamaci F, et al. Among authors: zoccali c. Kidney Int. 2005 Jun;67(6):2330-7. doi: 10.1111/j.1523-1755.2005.00338.x. Kidney Int. 2005. PMID: 15882276 Free article.

7

Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?

Kielstein JT, Zoccali C. Kielstein JT, et al. Among authors: zoccali c. Am J Kidney Dis. 2005 Aug;46(2):186-202. doi: 10.1053/j.ajkd.2005.05.009. Am J Kidney Dis. 2005. PMID: 16112037 Review.

8

Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.

Kielstein JT, Zoccali C. Kielstein JT, et al. Among authors: zoccali c. Curr Opin Nephrol Hypertens. 2008 Nov;17(6):609-15. doi: 10.1097/MNH.0b013e328314b6ca. Curr Opin Nephrol Hypertens. 2008. PMID: 18941355 Review.

9

Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.

Mallamaci F, Zoccali C. Mallamaci F, et al. Among authors: zoccali c. J Ren Nutr. 2009 Jan;19(1):25-8. doi: 10.1053/j.jrn.2008.10.013. J Ren Nutr. 2009. PMID: 19121766

10

Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease.

Yilmaz MI, Sonmez A, Saglam M, Gulec M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C. Yilmaz MI, et al. Among authors: zoccali c. Kidney Int. 2009 Jun;75(12):1316-1321. doi: 10.1038/ki.2009.63. Epub 2009 Mar 4. Kidney Int. 2009. PMID: 19262460 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,045 results

Search Page

Filters